dal-ACUTE

CETP inhibition improved the functionality of HDL in ACS patients, as measured by total cholesterol efflux. Dalcetrapib was terminated on 7 May 2012.
1 2
3 4
Download Slides (.ppt)

Editors

REGISTRATION IS FREE TO ALL HEALTHCARE PROFESSIONALS

 Supported by unrestricted medical
educational grants from

 Supporters have no editorial influence
over the content of this website